The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
详细信息 查看全文
- 作者：Sultan Linjawi ; Bruce W. Bode ; Louis B. Chaykin ; Jean-Pierre Courrèges…
- 关键词：Clinical trial ; GLP ; 1 receptor agonist ; IDegLira ; Insulin therapy ; Type 2 diabetes
- 刊名：Diabetes Therapy
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：8
- 期：1
- 页码：101-114
- 全文大小：1151KB
- 刊物主题：Internal Medicine; Diabetes; Cardiology; Endocrinology;
- 出版者：Springer Healthcare
- ISSN：1869-6961
- 卷排序：8
文摘
IntroductionThe progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs.